Bufalin-loaded mPEG-PLGA-PLL-cRGD nanoparticles: Preparation, cellular uptake, tissue distribution, and anticancer activity

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 3961-3969

  Yin, Peihao ^a   Wang, Yan ^a   Qiu, Yan Yan ^a   Hou, LiLi ^a   Liu, Xuan ^a   Qin, Jianmin ^a   Duan, Yourong ^b   Liu, Peifeng ^b   Qiu, Ming ^c   Li, Qi ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Bufalin; Colon cancer; Nanoparticles; Tumor target

Indexed keywords

BUFALIN; METHOXY POLYETHYLENE GLYCOL POLYLACTIC CO GLYCOLYTIC ACID POLYLYSINE CYCLIC ARGININE GLYCINE ASPARTIC ACID NANOPARTICLE; NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; COLON CANCER; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG TARGETING; DRUG UPTAKE; ENCAPSULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PARTICLE SIZE; SLOW RELEASE FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; TUMOR VOLUME; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BUFANOLIDES; CELL SURVIVAL; COLONIC NEOPLASMS; DRUG CARRIERS; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; OLIGOPEPTIDES; PARTICLE SIZE; POLYESTERS; POLYETHYLENE GLYCOLS; POLYLYSINE; SPECTROPHOTOMETRY, ULTRAVIOLET; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84870381900     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S32063     Document Type: Article

References (38)

1. Henley SJ, King JB, German RR, etal. Surveillance of screening-detected cancers (colon and rectum, breast, and cervix)-United States, 2004-2006. MMWR Surveill Summ. 2010;59(9):1-25.
2. Sjo OH, Berg M, Merok MA, etal. Peritoneal carcinomatosis of colon cancer origin: highest incidence in women and in patients with right-sided tumors. J Surg Oncol. 2011;104(7):792-797.
3. Lu CX, Nan KJ, Lei Y. Agents from amphibians with anticancer properties. Anticancer Drugs. 2008;19(10):931-939.
4. Cui X, Inagaki Y, Xu H, etal. Anti-hepatitis B virus activities of cinobufacini and its active components bufalin and cinobufagin in HepG2.2.15 cells. Biol Pharm Bull. 2010;33(10):1728-1732.
5. Qi F, Li A, Inagaki Y, etal. Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor. Int Immunopharmacol. 2011;11(3):342-349.
6. Han KQ, Huang G, Gu W, etal. Anti-tumor activities and apoptosis-regulated mechanisms of bufalin on the orthotopic transplantation tumor model of human hepatocellular carcinoma in nude mice. World J Gastroenterol. 2007;13(24):3374-3379.
7. Li H, Wang P, Gao Y, etal. Na+/K+-ATPase alpha3mediates sensitivity of hepatocellular carcinoma cells to bufalin. Oncol Rep. 2011;25(3): 825-830.
8. Amano Y, Cho Y, Matsunawa M, etal. Increased nuclear expression and transactivation of vitamin D receptor by the cardiotonic steroid bufalin in human myeloid leukemia cells. J Steroid Biochem Mol Biol. 2009;114(3-5):144-151.
9. Zhu Z, Yu Y, Wang K, etal. Effect of Bufalin on proliferation and apoptosis of human non-small cell lung cancer A549 cell. Zhongguo Fei Ai Za Zhi. 2010;13(9):841-845.
10. Li D, Qu X, Hou K, etal. PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells. Anticancer Drugs. 2009;20(1):59-64.
11. Yu CH, Kan SF, Pu HF, etal. Apoptotic signaling in bufalin-and cinobufagin-treated androgen-dependent and-independent human prostate cancer cells. Cancer Sci. 2008;99(12):2467-2476.
12. Gong LL, Li JX, Zhang HM. Progress on pharmacological action and preparation of venenum bufonis. Food and Drug. 2007;9(10):51-53.
13. Xu YZ, Fan Y, Zhang YL, etal. Effects of bufalin on apoptosis of human colon cancer SW620 cell. J Jiangsu University (Medicine Edition). 2007;17(6):515-517.
14. Xie CM, Chan WY, Yu S, etal. Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation. Free Radic Biol Med. 2011;51(7): 1365-1375.
15. Bick RJ, Poindexter BJ, Sweney RR, etal. Effects of Chan Su, a traditional Chinese medicine, on the calcium transients of isolated cardiomyocytes: cardiotoxicity due to more than Na, K-ATPase blocking. Life Sci. 2002;72(6):699-709.
16. Liu PF, Zhu MJ, Li YG, Wang HZ, Duan YR. The research on cytotoxicity and cellular uptake of mPEG-PLGA-PLL nanoparticles. Proceedings of 2009international conference on advanced fibers and polymer materials. 2009;1-2:1190-1192.
17. Kostakis C, Byard RW. Sudden death associated with intravenous injection of toad extract. Forensic Sci Int. 2009;188(1-3):e1-e5.
18. Dasgupta A, Emerson L. Neutralization of cardiac toxins oleandrin, oleandrigenin, bufalin, and cinobufotalin by digibind: monitoring the effect by measuring free digitoxin concentrations. Life Sci. 1998; 63(9):781-788.
19. Zhu D, Lu X, Hardy PA, etal. Nanotemplate-engineered nanoparticles containing gadolinium for magnetic resonance imaging of tumors. Invest Radiol. 2008;43(2):129-140.
20. Hu K, Zhu L, Liang H, etal. Improved antitumor efficacy and reduced toxicity of liposomes containing bufadienolides. Arch Pharm Res. 2011;34(9):1487-1494.
21. Weng Y, Jin J, Pan C, etal. Bioavailability and pharmacokinetics of bufadienolides-loaded lipid microspheres after different administrations to rats. J Lipid Sci Tech. 2011;113(9):1095-1105.
22. Li F, Wang Y, Liu Z, etal. Formulation and characterization of bufadienolides-loaded nanostructured lipid carriers. Drug Dev Ind Pharm. 2010;36(5):508-517.
23. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002;54(5):631-651.
24. Cegnar M, Kristl J, Kos J. Nanoscale polymer carriers to deliver chemotherapeutic agents to tumours. Expert Opin Biol Ther. 2005;5(12): 1557-1569.
25. Murphy EA, Majeti BK, Barnes LA, etal. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci U S A. 2008;105(27):9343-9348.
26. Ryppa C, Mann-Steinberg H, Biniossek ML, etal. In vitro and in vivo evaluation of a paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2] that targets integrin alpha v beta 3. Int J Pharm. 2009;368(1-2):89-97.
27. Stupack DG, Puente XS, Boutsaboualoy S, etal. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol. 2001;155(3):459-470.
28. Burkhart DJ, Kalet BT, Coleman MP, etal. Doxorubicin-formaldehyde conjugates targeting alphavbeta3integrin. Mol Cancer Ther. 2004; 3(12):1593-1604.
29. Zange R, Li YX, Kissel T. Biocompatibility testing of ABA triblock copolymers consisting of poly(L-lactic-co-glycolic acid) A blocks attached to a central poly(ethylene oxide) B block under in vitro conditions using different L929mouse fibroblasts cell culture models. J Control Release. 1998;56(1-3):249-258.
30. Sawhney AS, Pathak CP, Hubbell JA. Interfacial photopolymerization of poly(ethylene glycol)-based Anderson JM, Shive. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Delivery Rev. 1997;28(1):5-24.
31. Jain R, Shah NH, Malick AW, Rhodes CT. Controlled drug delivery by biodegradable poly(ester) devices: Different preparative approaches. Drug Dev Res. 1998;24(8):703-727.
32. Hudecz F, Kutassikovacs S, Mezo G, Szekerke M. Biodegradability of synthetic branched polypeptide with poly(l-lysine) backbone Biol. Chem Hoppe-Seyler. 1989;370(9):1019-1026.
33. Sawhney AS, Pathak CP, Hubbell JA. Interfacial photopolymerization of poly(ethylene glycol)-based hydrogels upon alginate-poly(l-lysine) microcapsules for enhanced biocompatibility. Biomaterial. 1993; 14(13):1008-1016.
34. Akizawa T, Kino K, Kinugasa E, et al. Clinical effects of a polyethylene glycol grafted cellulose membrane on thrombogenicity and biocompatibility during hemodialysis. ASAIO transactions/American Society for Artificial Internal Organs. 1990;36(3):M640-M642.
35. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1-2):271-284.
36. Li Q, Wang Y, Feng N, Fan Z, Sun J, Nan Y. Novel polymeric nanoparticles containing tanshinone IIA for the treatment of hepatoma. J Drug Target. 2008;16(10):725-732.
37. Liu D, Feng JF. Determination of apparent aqueous solubility and apparent oil-water partition coefficients of three bufadienolides composition. Zhongguo Zhong Yao Za Zhi. 2008;33(11):1256-1258.
38. Pan G, Lemmouchi Y, Akala EO, etal. Studies on PEGylated and drug-loaded PAMAM dendrimers. J Bioact Compat Pol. 2005;20(1):113-128.